Pernelle Lavaud, Bernadett Szabados, Rafael Morales-Barrera, Alfonso Gomez De Liano Lista, Pablo Maroto, Marine Gross Goupil, Andrea Necchi, Thomas Powles, Nick van Dijk, Alain Ravaud, Michiel S. van der Heijden, Joan Carles, Daniele Raggi, Patrizia Giannatempo, Ignacio Duran, Yohann Loriot, Teresa Alonso Gordoa, Daniel Castellano, Georgia Anguera Palacios, Félix Lefort, Guillermo de Velasco Oria de Rueda, Lista, Agd, van Dijk, N, de Rueda, Gdo, Necchi, A, Lavaud, P, Morales-Barrera, R, Gordoa, Ta, Maroto, P, Ravaud, A, Duran, I, Szabados, B, Castellano, D, Giannatempo, P, Loriot, Y, Carles, J, Palacios, Ga, Lefort, F, Raggi, D, Goupil, Mg, Powles, T, and Van der Heijden, Ms
Background: Immune checkpoint inhibitors (ICIs) are approved for first-line (cisplatin unfit, PD-L1+) and platinum-refractory urothelial carcinoma (UC). Still, most patients experience progressive disease (PD) as the best response. Although higher response rates to subsequent systemic treatment (SST) have been described, post-PD outcome data are scarce. Objective: To examine the outcome of UC patients who received SST and no SST after progressing to ICIs. Design, setting, and participants: A retrospective analysis of UC patients progressing to frontline or later-line anti-PD-1/PD-L1 therapy in 10 European institutions was conducted between March 2013 and September 2017. Intervention: Post-PD management as per standard practice. Outcome measurements and statistical analysis: Overall survival (OS) was analyzed with a Kaplan-Meier model. Cox regression was used for multivariate analysis (MV). Impact of SST on OS was examined with a time-varying covariate model. Results and limitations: A total of 270 UC patients with PD to ICIs (69 frontline, 201 later line) were analyzed. Of the patients, 57% of frontline-ICI-PD and 34% of later-line-ICI-PD patients received SST, and SST had an impact on OS in MV (frontline: hazard ratio [HR] 0.22, 95% confidence interval [CI] 0.10-0.51, p< 0.001; later line: HR 0.22, 95% CI 0.13-0.36, p< 0.001). In the frontline-ICI-PD group, median OS with and without SST was 6.8 mo (95% CI 5.0-8.6) and 1.9 mo (95% CI 0.9-3.0), respectively. High disease burden (three or more metastatic sites: HR 2.49, p = 0.03; simultaneous liver/bone metastases: HR 3.93, p = 0.03) predicted worse survival. In later-line-ICI-PD group, response to ICIs (HR 0.37, p = 0.03), longer exposure to ICIs (HR 0.89, p = 0.002), and bonemetastasis (HR 2.42, p< 0.001) predicted survival. The retrospective nature of this study and a lack of certain parameters limit the interpretation of our analysis. Conclusions: Patients progressing to frontline ICIs are at risk of early death, excluding them from experiencing potential benefit from chemotherapy Patient summary: Our analysis suggests that outcomes after failing immunotherapy are poor, particularly in UC patients who received no prior chemotherapy. (C) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.